PROPIO-100™

Category:

Description

Propio100™
Testosterone Propionate
100 mg/ml.

Description: Testosterone propionate is an androgen and anabolic steroid (AAS) medication which is used mainly in the treatment of low testosterone levels in men; it has also been used to treat breast cancer in women. It is given by injection into muscle, usually once every two, to three days. Testosterone propionate is a slower releasing anabolic steroid with a short half-life. This characteristic allows the user to run short testosterone propionate cycles of 8-10 weeks as optimal peak blood plasma levels are achieved at 2-4 weeks.

Medical uses: The original medical indication is for the treatment of androgen deficiency in male adults either in hypogonadism or andropause.

Non-medical uses: Testosterone propionate is often used for muscle mass building.

Contraindications: You should not be treated with this medicine if you are allergic to testosterone. Testosterone can increase your risk of heart attack, stroke, or death. Testosterone propionate is not for use in women who are pregnant since this medicine can harm an unborn baby or cause birth defects.

Possible side effects: Side effects of testosterone propionate include symptoms of masculinization like acne, increased hair growth, voice changes, and increased sexual desire.

Interactions: Androgens may decrease levels of thyroxin-binding globulin, resulting in decreased total T4 serum levels and increased resin uptake of T3 and T4. Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.

Pharmacology: Testosterone propionate is a prodrug of testosterone and is an androgen and anabolic–androgenic steroid (AAS). That is, it is an agonist of the androgen receptor (AR).


Additional information:

• Keep out of the reach of children.
• Do not store at a temperature higher than 30ºC.
• Do not consume Propio100™ after the expiration date.
• Each ml contains 100 mg of Propio100™ (Testosterone Propionate).
• Medical prospectus made and approved in August 2018.